BNT327

PreclinicalSmall molecule

BioNTech

BNT327 is one of 135 small molecule programs targeting Lung Cancer. It is currently in Preclinical.

Indications

Total Trials

Active Trials

134

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Breast CancerActive, not recruiting

Colorectal CancerActive, not recruiting

Advanced Lung CancerRecruiting

Locally Advanced Breast CancerRecruiting

Lung CancerPhase 1/Phase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 1/Phase 2

Active, not recruiting

Breast CancerPhase 1/Phase 2

Active, not recruiting

Colorectal CancerPhase 1/Phase 2

Active, not recruiting

Advanced Lung CancerPreclinical

Recruiting

Locally Advanced Breast CancerPreclinical

Recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Tecentriq

Roche

Preclinical

36 2

Trodelvy

Gilead

Preclinical

37 3

Halaven

Eisai

Preclinical

38 4

Tykerb

GSK

Preclinical

80 5

Adriamycin

GGynecologic Oncology Group

Preclinical

87 6

Avastin

BBio-Thera Solutions

Preclinical

153 7

Nolvadex

SSan Diego Pacific Oncology & Hematology Associates

Preclinical

78 8

Prolia

Amgen

Preclinical

14 9

Gemzar

GGynecologic Oncology Group

Megace

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Advanced Solid Tumors

NCT07147348

Q3 2029

PreclinicalRecruiting

Locally Advanced Breast Cancer

NCT06827236

Q1 2030

Phase 1/2Recruiting

Non-Small Cell Lung Cancer

NCT07111520

Q2 2030

Phase 2Recruiting

Advanced/metastatic Solid Tumors

NCT06953089

Clinical

Trials by Indication[1]

Advanced/Metastatic Solid Tumors2 trials

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

Recruiting·DDualityBio Inc.·Phase 2·NCT06953089·492 enrolled

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

Recruiting·DDualityBio Inc.·Phase 1/2·NCT05438329·1,123 enrolled

Advanced Solid Tumors1 trial

A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors

Recruiting· BioNTech logo

BioNTech·Phase 1/2·NCT07147348·375 enrolled

Non-Small Cell Lung Cancer1 trial

A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

Recruiting· BioNTech logo

BioNTech·Phase 1/2·NCT07111520·420 enrolled

Metastatic Colorectal Cancer1 trial

A Phase I/II, Randomized, Multi-site Trial to Investigate the Efficacy and Safety of BNT314 in Combination With Pumitamig and Chemotherapy in Participants With Metastatic Colorectal Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT07079631·482 enrolled

Advanced Lung Cancer1 trial

A Phase Ib/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, Pharmacokinetics, and Recommended Combination Dose of BNT324 With BNT327 in Participants With Advanced Lung Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT06892548·594 enrolled

1 more indication

Locally Advanced Breast Cancer1 trial

A Phase I/II, Multi-site, Open-label, Two-part Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of BNT323 in Combination With BNT327 in Participants With Advanced Breast Cancer

Recruiting· BioNTech logo

BioNTech·Preclinical·NCT06827236·380 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for BNT327. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BNT327 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BNT327. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — BioNTech company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BioNTech

BNT327

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q3 2029

Q1 2030

Q2 2030

Trials by Indication[1]

Advanced/Metastatic Solid Tumors2 trials

Advanced Solid Tumors1 trial

Non-Small Cell Lung Cancer1 trial

Metastatic Colorectal Cancer1 trial

Advanced Lung Cancer1 trial

Locally Advanced Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News